Article Listing - Novartis' Tekturna and Diovan work in synergy
EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib
13 June 2013
Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech firm Celgene (Nasdaq: CELG) presented positive data from a third Phase III randomized controlled study, dubbed PALACE 3, of apremilast in psoriatic arthritis.
Turkey's NSCLC drug market forecast to expand at 7% a year through 2017
13 June 2013
From 2012 to 2017, the non-small-cell lung cancer (NSCLC) market in Turkey will increase at an annual rate of 7%, reaching a value of $73 million in 2017, according to a new report from health care advisory firm Decision Resources.
Sunesis Pharma's VALOR trial of vosaroxin should continue with no change, says DSMB
13 June 2013
Sunesis Pharmaceuticals (Nasdaq: SNSS) says that the independent Data and Safety Monitoring Board (DSMB) for the VALOR trial has completed its latest periodic safety review and recommended that the trial continue as planned without changes to study conduct.
Sagent Pharma expands voluntary withdrawal of vecuronium inj vials
13 June 2013
US drugmaker Sagent Pharmaceuticals (Nasdaq: SGNT) said today (June 13) that it is expanding its voluntary nationwide recall of vecuronium bromide for injection 10mg (NDC number 25021-657-10) manufactured by Turkey-based Mustafa Nevzat Ilac Sanayii (MN Pharmaceuticals) and distributed by Sagent. This recall is being conducted with the knowledge of the US Food and Drug Administration.
Increased focus on generics and biosimilars only way to make European health care sustainable, says EGA
13 June 2013
Addressing delegates at the 19th European Generic medicines Association (EGA) Annual Conference in Athens, Greece, its president Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe; benefiting society and patients and increasing the competitiveness and innovative capacity of this strategic industry.
Amgen's trebananib meets primary end-point in Ph III study of recurrent ovarian cancer
13 June 2013
USA-based Amgen (Nasdaq: AMGN), the world's largest independent biotech firm, has announced that the Phase III TRINOVA-1 trial evaluating trebananib (AMG 386) plus paclitaxel versus placebo plus paclitaxel in recurrent ovarian cancer met its primary endpoint of progression-free survival (PFS).
First approved new class of IBS-C therapy, Constella, now available in Europe
13 June 2013
Spain's largest drugmaker Almirall (ALM: MC) and US partner Ironwood Pharmaceuticals, (Nasdaq: IRWD) today (June 13) announced the launch of Constella (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C, in Europe. Constella is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.
Rising drug resistance driving early-line use of powerful antibiotics, according to surveyed EU5 physicians
13 June 2013
More than half of physicians surveyed by health care advisory firm, Decision Resources from the EU5 (France, Germany, Italy, Spain and the UK) prescribe carbapenems, especially meropenem (Cubist/AstraZeneca's Merrem/Meronem; Dainippon Sumitomo's Meropen; generics) and imipenem/cilastatin (Merck's Primaxin/Tienam; generics), as first- or second-line therapy for Gram-negative infections (GNIs) due to ESBL-producing Enterobacteriaceae.
Generics triple-therapy just as effective as brand-name Enbrel, new study shows
13 June 2013
Global biotech leader Amgen's (Nasdaq: AMGN) branded drug Enbrel (etanercept) is no more effective in treating rheumatoid arthritis than cheaper generic drugs, according to new research published in the Journal of the Medical Association, funded by the US Department of Veteran Affairs.
Teva and Active Biotech to move forward with laquinimod on positive Ph IIa results in active lupus nephritis
13 June 2013
Israel's Teva Pharmaceutical Industries (NYSE: TEVA) and Swedish partner Active Biotech (OMX NORDIC: ACTI) have released positive results of a Phase IIa study of oral laquinimod designed to assess safety, tolerability and clinical efficacy in patients with active lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE or lupus) that can lead to chronic kidney failure.
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
